Rhythmic therapeutic exercise program for breast cancer survivors

Not Applicable

• Conditions: Fatigue in breast cancer survivors; Signs and Symptoms

• Registration Number: ISRCTN13777029
• Lead Sponsor: Hellenic Cancer Society

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-01-13
• Last Update Posted: 27 February 2023
• Study Completion: 2025-01-06

Recruitment & Eligibility

• Status: Ongoing
• Sex: Female
• Target Recruitment: 65

Inclusion Criteria

1. Breast cancer disease-free women aged 45-60 years (meaning that they completed their oncology treatment 2 to 6 months before enrollment in the study), except if they are receiving hormonotherapy
2. Willing to be assigned to any of the two study intervention groups

Exclusion Criteria

1. Cognitive impairments
2. Neurological disorders
3. Cardiovascular diseases or high blood pressure not controlled with medication
5. Surgery on lower limbs affecting gait within the previous 6 months
6. Medical or other musculoskeletal problems that could affect the ability to complete objective assessments or exercise with safety
7. Cancer recurrence

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Cancer-related fatigue will be evaluated using the Greek version of the Multidimensional Fatigue Inventory (MFI-Greek version) and the Greek version of the Modified Fatigue Impact Scale (MFIS) at baseline, 8, and 16 weeks<br> 2. Functional mobility will be assessed using the Timed Up and Go Test at baseline, 8, and 16 weeks<br> 3. Physical activity will be assessed using 6 minutes walking test (6MWS) at baseline, 8, and 16 weeks<br> 4. Quality of life will be evaluated using the Greek version of the SF-36 Scale at baseline, 8, and 16 weeks<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Grip strength will be assessed using a hand dynamometer at baseline, 8, and 16 weeks<br> 2. Lower limbs’ muscle strength will be assessed using the 30-sec sit-to-stand test at baseline, 8, and 16 weeks<br> 3. Balance will be assessed using the Functional Reach Test at baseline, 8, and 16 weeks<br> 4. Depression and anxiety will be assessed using the Greek version of the Depression, Anxiety and Stress Scale-21 (DASS-21) at baseline, 8, and 16 weeks<br>